Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025

Description

Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon hematological disorder that is acquired, and it is characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins found on the surface of blood cells. This condition is debilitating and can lead to premature death, as well as impaired blood cell production. PNH manifests through a variety of symptoms, including fatigue, shortness of breath, abdominal pain, and the formation of blood clots known as thrombosis.

The primary approaches to treating paroxysmal nocturnal hemoglobinuria (PNH) involve the use of medications, bone marrow transplantation, blood transfusion, immunosuppressive therapy, and other methods. Medications are substances specially designed and formulated for the diagnosis, treatment, prevention, or alleviation of medical conditions, diseases, or symptoms in both humans and animals. Various diagnostic techniques, such as flow cytometry and high-resolution mass spectrometry, are utilized by a range of end users, including hospitals, clinics, and others.

The paroxysmal nocturnal hemoglobinuria market research report is one of a series of new reports from The Business Research Company that provides paroxysmal nocturnal hemoglobinuria market statistics, including paroxysmal nocturnal hemoglobinuria industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria market share, detailed paroxysmal nocturnal hemoglobinuria market segments, market trends and opportunities and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria industry. This paroxysmal nocturnal hemoglobinuria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The paroxysmal nocturnal hemoglobinuria (PNH) market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.68 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.

The paroxysmal nocturnal hemoglobinuria (PNH) market size is expected to see strong growth in the next few years. It will grow to $6.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

The growing prevalence of blood disorders and bone marrow-related conditions is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood disorders are conditions that affect the production, function, and composition of blood and its components, while bone marrow-related disorders involve insufficient production of red, white blood cells, or platelets, or the production of damaged or defective blood cells. PNH, a rare blood disorder linked to bone marrow failure, occurs when a genetic mutation disrupts the function of red blood cells and platelets. For example, in August 2022, Cancer Australia reported that around 5,202 new cases of leukemia were expected in 2022, with 3,198 cases in males and 2,004 cases in females. The likelihood of being diagnosed with leukemia by age 85 is 1 in 58 (1.7%) overall, with males at a higher risk (1 in 47 or 2.1%) compared to females (1 in 77 or 1.3%). This increasing incidence of blood and bone marrow disorders is driving the growth of the PNH market.

The growing requirement for blood transfusions is poised to be a driving force behind the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood transfusion is a medical procedure that involves the transfer of blood or blood products from a donor to a recipient. For individuals with paroxysmal nocturnal hemoglobinuria (PNH), blood transfusions can offer temporary relief from the symptoms and complications associated with this condition. For instance, in June 2023, the World Health Organization, an intergovernmental organization headquartered in Switzerland, reported that high-income nations, which account for only 16% of the global population, contributed significantly to blood donations, comprising 40% of the total 118.5 million blood donations made worldwide. Additionally, in December 2022, the Government of Canada reported that the United Kingdom experienced an upsurge in blood donations, with 1.7 million donations made across the country in 2021. Consequently, the escalating demand for blood transfusions is a key factor driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Leading companies in the paroxysmal nocturnal hemoglobinuria (PNH) market are focusing on the development of innovative therapies, such as injectable C5 inhibitors, to maintain their competitive edge. Injectable C5 inhibitors are monoclonal antibodies that block complement component C5, helping to reduce inflammation and tissue damage associated with autoimmune diseases, including PNH. For example, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, received priority review approval from China's National Medical Products Administration (NMPA) for its PNH treatment. This makes China the first country to approve PIASKY, allowing it to enter negotiations for the National Reimbursement Drug List (NRDL) within the same year. PNH, a rare disease, affects an estimated 12,740 individuals in China, presenting substantial market opportunities.

In March 2024, Gilead Sciences, Inc., a US-based biopharmaceutical company specializing in developing medicines for life-threatening diseases, acquired Cymabay Therapeutics, Inc. for $4.3 billion. This acquisition strengthens Gilead's liver disease portfolio, particularly with the addition of seladelpar, a promising treatment for primary biliary cholangitis that addresses significant unmet medical needs. Cymabay Therapeutics, Inc., also based in the US, is focused on developing seladelpar as a potential treatment for paroxysmal nocturnal hemoglobinuria (PNH).

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paroxysmal nocturnal hemoglobinuria (PNH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paroxysmal nocturnal hemoglobinuria (pnh) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for paroxysmal nocturnal hemoglobinuria (pnh) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The paroxysmal nocturnal hemoglobinuria (pnh) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Medications; Bone Marrow Transplantation; Blood Transfusion; Immunosuppressive Therapy; Other Treatment Types
2) By Diagnosis Type: Flow Cytometry; High-Resolution Mass Spectrometry; Other Diagnosis Types
3) By End Use: Hospitals; Clinics; Other End Users
Subsegments:
1) By Medications: Eculizumab; Ravulizumab; Complement Inhibitors; Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation; Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion; Platelet Transfusion; Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids; Azathioprine; Cyclophosphamide; Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies; Management Of Complications
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Pvt Ltd; F. Hoffmann-La Roche AG.; Novartis AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r28693

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Characteristics

3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Trends And Strategies

4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Growth Analysis And Strategic Analysis Framework

5.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Growth Rate Analysis
5.4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Total Addressable Market (TAM)

6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segmentation

6.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medications
Bone Marrow Transplantation
Blood Transfusion
Immunosuppressive Therapy
Other Treatment Types
6.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Flow Cytometry
High-Resolution Mass Spectrometry
Other Diagnosis Types
6.3. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
linics
Other End Users
6.4. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Eculizumab
Ravulizumab
Complement Inhibitors
Supportive Care Medications
6.5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Bone Marrow Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Allogeneic Stem Cell Transplantation
Autologous Stem Cell transplantation
6.6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Red blood Cell Transfusion
Platelet Transfusion
Fresh Frozen Plasma Transfusion
6.7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Immunosuppressive Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Azathioprine
Cyclophosphamide
Mycophenolate Mofetil
6.8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Supportive Therapies
Management Of Complications

7. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Regional And Country Analysis

7.1. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

8.1. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

9.1. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
9.2. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

10.1. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

11.1. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
11.2. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

12.1. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

13.1. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

14.1. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
14.2. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

15.1. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
15.2. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

16.1. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

17.1. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

18.1. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

19.1. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

20.1. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

21.1. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
21.2. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

22.1. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

23.1. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
23.2. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

24.1. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
24.2. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

25.1. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
25.2. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

26.1. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
26.2. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

27.1. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

28.1. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
28.2. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

29.1. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Overview
29.2. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape And Company Profiles

30.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape
30.2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Pvt Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche AG. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Other Major And Innovative Companies

31.1. Thermo Fisher Scientific Inc.
31.2. Takeda Pharmaceutical Company Limited
31.3. Amgen Inc.
31.4. GE Healthcare
31.5. Regeneron Pharmaceuticals Inc.
31.6. CSL Behring LLC
31.7. Biogen Inc.
31.8. Vertex Pharmaceuticals Incorporated
31.9. Grifols S.A.
31.10. Genentech Inc.
31.11. Shire plc
31.12. Alnylam Pharmaceuticals Inc.
31.13. Innovent Biologics Inc.
31.14. Bioverativ Inc.
31.15. CinnaGen Co

32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

34. Recent Developments In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market High Potential Countries, Segments and Strategies

35.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2029 - Countries Offering Most New Opportunities
35.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2029 - Segments Offering Most New Opportunities
35.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer